Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ZVRA

Zevra Therapeutics Inc

Apr 26 • 04:00PM ET

4.52

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC VTWV DFAS RYLD AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.30	Insider Own	0.74%	Shs Outstand	43.43M	Perf Week	0.00%
Market Cap	196.30M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	43.10M	Perf Month	-23.91%
Income	-46.05M	PEG	-	EPS next Q	-0.47	Inst Own	29.67%	Short Float	5.50%	Perf Quarter	-24.35%
Sales	27.46M	P/S	7.15	EPS this Y	-22.05%	Inst Trans	-5.35%	Short Ratio	9.46	Perf Half Y	2.96%
Book/sh	1.49	P/B	3.03	EPS next Y	67.44%	ROA	-31.99%	Short Interest	2.37M	Perf Year	-12.74%
Cash/sh	0.99	P/C	4.56	EPS next 5Y	-	ROE	-62.37%	52W Range	3.89 - 7.28	Perf YTD	-30.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	51.89%	ROI	-68.34%	52W High	-37.91%	Beta	1.88
Dividend TTM	-	Quick Ratio	1.18	Sales past 5Y	44.97%	Gross Margin	85.61%	52W Low	16.20%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	1.18	EPS Y/Y TTM	-7.51%	Oper. Margin	-180.63%	RSI (14)	30.19	Volatility	2.77% 4.83%
Employees	69	Debt/Eq	0.71	Sales Y/Y TTM	162.58%	Profit Margin	-167.69%	Recom	1.00	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-52.95%	Payout	-	Rel Volume	0.63	Prev Close	4.52
Sales Surprise	12.51%	EPS Surprise	-90.09%	Sales Q/Q	469.94%	Earnings	Mar 28 AMC	Avg Volume	250.77K	Price	4.52
SMA20	-6.43%	SMA50	-21.07%	SMA200	-13.53%	Trades		Volume	157,431	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Reiterated	Maxim Group	Buy	$12 → $18
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy	$12

Apr-15-24 05:01PM	Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting (GlobeNewswire)
Apr-10-24 07:30AM	Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility (GlobeNewswire)
Apr-01-24 12:46PM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q4 2023 Earnings Call Transcript (Insider Monkey) -11.03%
Mar-29-24 12:07PM	Q4 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 09:52PM	ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:11PM	Loading…
06:11PM	Zevra Therapeutics Inc (ZVRA) Earnings: A Mixed Bag Against Analyst Estimates with Significant ... (GuruFocus.com)
04:53PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:32PM	Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire)
Mar-26-24 04:30PM	Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Mar-25-24 04:30PM	Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-24 10:00AM	Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-18-24 07:30AM	Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024 (GlobeNewswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-04-24 07:30AM	Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) -12.15%
Feb-28-24 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
03:49AM	Loading…
Feb-15-24 03:49AM	Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks) +8.79%
Feb-06-24 07:30AM	Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-23-24 07:30AM	Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors (GlobeNewswire)
Jan-08-24 07:30AM	Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C (GlobeNewswire) +6.90%
Jan-04-24 08:55AM	Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer (GlobeNewswire)
Dec-27-23 07:30AM	Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration (GlobeNewswire) +10.71%
Nov-20-23 07:30AM	Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company (GlobeNewswire)
Nov-12-23 08:42AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 08:17AM	Zevra Therapeutics Inc (ZVRA) Reports Q3 2023 Financial Results (GuruFocus.com)
07:08AM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-31-23 07:30AM	Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET (GlobeNewswire)
Oct-19-23 07:30AM	Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October (GlobeNewswire)
Oct-10-23 07:30AM	Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director (GlobeNewswire)
Oct-05-23 07:30AM	Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting (GlobeNewswire)
07:30AM	Loading…
Oct-02-23 07:30AM	Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia (GlobeNewswire)
Sep-20-23 07:30AM	Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-23 08:00PM	Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023 (GlobeNewswire)
Sep-05-23 07:30AM	Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.51%
Sep-04-23 09:55AM	How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51% (Zacks)
Sep-01-23 07:31AM	Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up (Zacks) +6.11%
Aug-31-23 12:13PM	Struggling Newton biotech Acer Therapeutics scooped up by Florida firm (American City Business Journals)
07:30AM	Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product (GlobeNewswire)
Aug-19-23 07:40AM	Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-17-23 09:55AM	Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-15-23 12:15AM	Q2 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 07:42AM	Zevra Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 04:45PM	Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster (GlobeNewswire)
Aug-02-23 07:30AM	Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023 (GlobeNewswire)
Jul-19-23 10:30AM	Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long (Simply Wall St.)
07:30AM	Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference (GlobeNewswire)
Jun-20-23 07:30AM	Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 (GlobeNewswire) +6.88%
Jun-13-23 07:30AM	Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest (GlobeNewswire)
Jun-03-23 07:30AM	Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 (GlobeNewswire)
May-16-23 06:22AM	Q1 2023 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +7.11%
May-15-23 05:55PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:59PM	Zevra Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:05PM	Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 07:30AM	Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023 (GlobeNewswire)
May-09-23 07:30AM	Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023 (GlobeNewswire) -9.96%
May-08-23 07:30AM	Zevra Announces Board of Directors and Leadership Changes (GlobeNewswire)
May-03-23 07:30AM	Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy (GlobeNewswire)
Apr-17-23 04:05PM	Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevras Transformation Strategy (GlobeNewswire)
06:18AM	Why Investors Shouldn't Be Surprised By Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 31% Share Price Surge (Simply Wall St.)
Apr-04-23 07:30AM	Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy (GlobeNewswire)
Mar-30-23 07:30AM	Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors (GlobeNewswire)
Mar-17-23 07:30AM	Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative (GlobeNewswire)
Mar-15-23 07:26AM	Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders (GlobeNewswire) -5.01%
Mar-07-23 07:00AM	Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates (GlobeNewswire) -19.44%
Mar-06-23 07:30AM	Zevra Therapeutics to Present at 35th Annual Roth Conference (GlobeNewswire)

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Thomas	Director	Sep 06 '23	Buy	4.88	10,000	48,764	10,000	Sep 06 04:39 PM
Clifton R. LaDuane	CFO, Secretary & Treasurer	Sep 06 '23	Buy	4.96	1,000	4,959	15,309	Sep 06 05:11 PM
Bode John B	Director	Sep 05 '23	Buy	5.13	10,000	51,333	20,000	Sep 06 04:40 PM
Schafer Joshua	CCO & EVP, Bus. Development	Sep 05 '23	Buy	5.13	500	2,564	3,500	Sep 06 05:11 PM
Watton Corey Michael	Director	Jun 23 '23	Buy	5.95	275	1,636	1,000	Jun 26 04:19 PM
Watton Corey Michael	Director	Jun 09 '23	Buy	5.52	325	1,794	725	Jun 13 08:35 PM
Watton Corey Michael	Director	May 30 '23	Buy	5.11	400	2,042	400	May 31 11:34 AM
Schafer Joshua	CCO & EVP, Bus. Development	May 19 '23	Buy	5.42	1,000	5,416	3,000	Jun 30 04:14 PM
Bode John B	Director	May 18 '23	Buy	5.04	10,000	50,418	10,000	May 19 05:53 PM
Clifton R. LaDuane	CFO, Secretary & Treasurer	May 18 '23	Buy	4.95	2,740	13,562	13,742	May 18 04:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVRA

Zevra Therapeutics Inc

Upgrade your FINVIZ experience